Clinical Trials in San Francisco

Showing 2421-2440 of 11,161 trials

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

NCT03501979

A phase 2 non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab with capecitabine for the treatment of leptomeningeal metastases in HER2-neu positive breast cancer.

Metastatic Breast CancerLeptomeningeal Disease

University of Alabama at Birmingham17 participantsStarted Feb 2019

Birmingham, Alabama, United States • San Francisco, California, United States • Washington D.C., District of Columbia, United States +6 more locations

COMPLETEDPhase 3< 1 mile

Long-Term Evaluation of BIIB067 (Tofersen)

NCT03070119

The primary objective of the study is to evaluate the long-term safety and tolerability of BIIB067 (tofersen) in participants with amyotrophic lateral sclerosis (ALS) and confirmed superoxide dismutase 1 (SOD1) mutation. The secondary objectives are to evaluate the pharmacokinetic (PK), pharmacodynamic (PD), biomarker effects, and efficacy of BIIB067 administered to participants with ALS and a confirmed SOD1 mutation.

ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation

Biogen139 participantsStarted Mar 2017

Phoenix, Arizona, United States • La Jolla, California, United States • San Francisco, California, United States +27 more locations

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

Long-Term Evaluation of BIIB067 (Tofersen)

Find Trials by Condition in San Francisco

A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

Methylglyoxal (MGO) Lowering Cocktail to Reduce Appetite in Obese Individuals

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type I (MPS I)

Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse Events

Telehealth 2.0: Evaluating Effectiveness and Engagement Strategies for CPT-Text for PTSD

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone

Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

A Study of LY3549492 in Healthy Weight Adult Participants

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction

Post-approval Study of New Enrolment Patients Undergoing Bilateral Treatment With the VisuMax SMILE Procedure

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma